Biliary Tract CancersPhase 2NCT07793253
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
A Phase 2 study testing Daraxonrasib in people with Biliary Tract Cancers and Intrahepatic Cholangiocarcinoma (Icc), run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins at 1 site in United States.
Trial summary
The purpose of this study is to evaluate the anti-tumor efficacy of daraxonrasib monotherapy in patients with unresectable or advanced/metastatic, KRAS-mutant BTC who have progressed on or are intolerant of 1st line systemic therapy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma
- What is being tested?
- Daraxonrasib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 55 participants
- Where
- 1 siteUnited States
- Study dates
- Nov 2026to Nov 2030
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Unresectable locally advanced or metastatic histologically or cytologically confirmed biliary tract cancer
- Must have documented disease progression or intolerance of one prior systemic chemotherapy regimen (with or without immunotherapy) for unresectable and/or advanced stage disease.
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.
- Have measurable disease based on RECIST 1.1.
- Documented KRAS mutation
Show all 12Show fewer
- Adequate organ and marrow function defined by study-specified laboratory tests and procedures.
- Willingness to provide serial tissue and blood samples for mandatory translational research.
- Evidence of post-menopausal status or a negative pregnancy test in women of childbearing potential (WOCBP).
- All participants must agree to use acceptable form of birth control while on study.
- Ability to take oral medications and willingness to keep daily adherence record in a medication diary.
- Must understand the study regimen, its requirements, risks and discomforts and is able and willing to sign the informed consent form in accordance with regulatory and institutional guidelines.
Who cannot join
- Any systemic anti-cancer therapy for advanced BTC within 3 weeks of enrollment or 5 half-lives of the drug, whichever is shorter.
- Prior treatment with any KRAS, RTK, or MEK inhibitor or other RAS-pathway targeting signal transduction inhibitor agents
- Major surgery, extended field radiotherapy, or local regional therapy within 4 weeks from first dose of study drug, limited field radiotherapy within 2 weeks of first dose, or failure to recover from side effects of these prior therapies
- Known additional malignancy that is progressing and requires active treatment.
- Receiving concomitant medications that interfere with Daraxonrasib.
- Significant cardiovascular disease.
Show all 19Show fewer
- Significant cardiac conduction abnormalities.
- Impaired gastrointestinal function.
- Active autoimmune disease
- Clinically active ascites.
- Active uncontrolled infection requiring systemic therapy within 72 hours prior to C1D1.
- Known history of human immunodeficiency virus (HIV).
- Active or chronic hepatitis B or hepatitis C.
- Known history of central nervous system (CNS) metastases and/or history of uncontrolled seizures.
- Any uncontrolled acute or chronic medical illness.
- History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- Pregnant or breastfeeding
- Patient is unwilling or unable to follow the study schedule for any reason.
- Has known psychiatric or substance use disorder that would interfere with cooperation with the requirements of the trial.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231
About this study
Official title: A Multi-Institutional Phase 2 Evaluation of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
The purpose of this study is to evaluate the anti-tumor efficacy of daraxonrasib monotherapy in patients with unresectable or advanced/metastatic, KRAS-mutant BTC who have progressed on or are intolerant of 1st line systemic therapy.
- Conditions
- Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma, Ampulla of Vater Carcinoma, Ampullary Carcinoma
- Being tested
- Daraxonrasib
- Keywords
- Daraxonrasib (RMC-6236), KRAS (Kirsten rat sarcoma virus) mutations, Immunotherapy, Biliary Tract Cancer, Liver Cancer, Carcinoma, Metastatic Cancer, Gastrointestinal Cancer
- Medical subject headings
- Biliary Tract Neoplasms, Cholangiocarcinoma, Cirrhosis, Familial, with Pulmonary Hypertension, Gallbladder Neoplasms, Liver Neoplasms, Carcinoma, Neoplasm Metastasis, Gastrointestinal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DaraxonrasibDrug
Also called RMC-6236
Daraxonrasib will be taken at a dose of 300 mg orally once daily in 28-day cycles.
| Study group | Role | What they receive |
|---|---|---|
| Daraxonrasib | Experimental | Not described Receives: Drug: Daraxonrasib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Objective Response (ORR)
ORR is defined as the proportion of patients who achieved a complete response (CR) or partial response (PR) based on the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Subjects who discontinue due to toxicity or clinical progression prior to post-baseline tumor assessments will be considered as non-responders.
Measured: 4 years
Secondary outcomes (5)
Overall Survival (OS)
OS is defined as the number of months from the date of treatment initiation until death from any cause or end of follow-up. OS will be censored on the date the participant was last known to be alive for participants without documentation of death at the time of analysis. Estimation based on the Kaplan-Meier curve.
Measured: 4 years
Progression free survival (PFS)
PFS is defined as the number of months from the date of treatment initiation to radiographic disease progression using RECIST v1.1 criteria or death due to any cause, whichever occurs first. Progression of disease (PD) will be censored at the date of the last scan for participants without documentation of disease progression at the time of analysis. Progression will be censored at the time of treatment initiation for participants that do not have a follow up scan. Estimation based on the Kaplan-Meier curve.
Measured: 4 years
Duration of response (DOR)
DOR, defined as the number of months from the date of response to the date of clinically determined disease progression or death from any cause, in participants achieving CR or PR.
Measured: 4 years
Disease control rate (DCR)
DCR is defined as the proportion of participants who achieved CR, PR and stable disease (SD). Stable disease is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Measured: 4 years
Unacceptable Toxicities
Number of participants experiencing treatment-related adverse events requiring treatment discontinuation. Defined using NCI CTCAE version 6.0
Measured: 4 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Aug 2026
- Study startNov 2026 (estimated)
- Primary completionNov 2030 (estimated)
- Study completionNov 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Biliary Tract CancersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 55 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Sponsor type
- University, hospital or other
- Collaborators
- Revolution Medicines, Inc., Cholangiocarcinoma Foundation
- Responsible party
- Sponsor
- Investigators
- Nilo Azad, MD, Principal investigator, Johns Hopkins University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07793253
- Sponsor's protocol ID
- J2695
- Other IDs
- IRB00560104
- Status last verified
- Aug 2026
- First submitted
- 25 Aug 2026
- Last updated
- 28 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-Institutional Phase 2 Evaluation of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
- ClinicalTrials.gov ID
- NCT07793253
- Acronym / sponsor ID
- J2695
- Conditions
- Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma, Ampulla of Vater Carcinoma, Ampullary Carcinoma
- Keywords
- Daraxonrasib (RMC-6236), KRAS (Kirsten rat sarcoma virus) mutations, Immunotherapy, Biliary Tract Cancer, Liver Cancer, Carcinoma, Metastatic Cancer, Gastrointestinal Cancer
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 55 participants (estimated)
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsUniversity, hospital or other
- Collaborators
- Revolution Medicines, Inc., Cholangiocarcinoma Foundation
- Study start
- Nov 2026 (estimated)
- Primary completion
- Nov 2030 (estimated)
- Study completion
- Nov 2030 (estimated)
- First posted
- 28 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the anti-tumor efficacy of daraxonrasib monotherapy in patients with unresectable or advanced/metastatic, KRAS-mutant BTC who have progressed on or are intolerant of 1st line systemic therapy.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Daraxonrasib | Experimental | Drug: Daraxonrasib |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Unresectable locally advanced or metastatic histologically or cytologically confirmed biliary tract cancer
- Must have documented disease progression or intolerance of one prior systemic chemotherapy regimen (with or without immunotherapy) for unresectable and/or advanced stage disease.
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.
- Have measurable disease based on RECIST 1.1.
Key exclusion criteria (19 listed)
- Any systemic anti-cancer therapy for advanced BTC within 3 weeks of enrollment or 5 half-lives of the drug, whichever is shorter.
- Prior treatment with any KRAS, RTK, or MEK inhibitor or other RAS-pathway targeting signal transduction inhibitor agents
- Major surgery, extended field radiotherapy, or local regional therapy within 4 weeks from first dose of study drug, limited field radiotherapy within 2 weeks of first dose, or failure to recover from side effects of these prior therapies
- Known additional malignancy that is progressing and requires active treatment.
- Receiving concomitant medications that interfere with Daraxonrasib.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DaraxonrasibAlso: RMC-6236Daraxonrasib will be taken at a dose of 300 mg orally once daily in 28-day cycles. | Drug | Daraxonrasib |
Primary outcome
Objective Response (ORR)
Time frame: 4 years
ORR is defined as the proportion of patients who achieved a complete response (CR) or partial response (PR) based on the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Subjects who discontinue due to toxicity or clinical progression prior to post-baseline tumor assessments will be considered as non-responders.
5 secondary outcomes
Overall Survival (OS)
Time frame: 4 years
Progression free survival (PFS)
Time frame: 4 years
Duration of response (DOR)
Time frame: 4 years
Disease control rate (DCR)
Time frame: 4 years
Unacceptable Toxicities
Time frame: 4 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Aug 2026.
Related trials for Biliary Tract Cancers
RecruitingObservational study
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
Colorectal Neoplasms, Gastric Neoplasms
Enrolling by invitationPhase 2
Vedotin for Injection in Second-line or Later Treatment of Advanced Biliary Tract Cancer
Biliary Tract Neoplasms
RecruitingPhase 1/2
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Recurrent or Metastatic Solid Tumors
Active, not recruitingPhase 2
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
Hepatocellular Cancer, Hepatocellular Carcinoma
RecruitingPhase 2
Phase II Study of Primary Tumor Resection and Selective Lymph Node Dissection Followed by RT for BTC With Lymph Node Metastases
Biliary Tract Cancer (BTC), Surgery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Nilo Azad, MD principal investigator
Johns Hopkins University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Daraxonrasib in people with Biliary Tract Cancers and Intrahepatic Cholangiocarcinoma (Icc), run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 28 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Colleen Apostal, RN (410-614-3644, GIClinicalTrials@jhmi.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Objective Response (ORR) (time frame: 4 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2026.